Video

Mirus Bio Bio-Expo Live February 2025: Upstream Bioprocessing

Source: Mirus Bio

Adeno-associated virus (AAV) vector manufacturing remains a critical bottleneck in the cell and gene therapy industry, especially when targeting indications requiring medium to high dosing. View an informative webinar where we show a next-generation transfection platform that improves AAV production titers and can yield AAV vectors with high percent full particles. Our presentation demonstrates how this integrated system tackles production hurdles by delivering:

  • Higher AAV titers
  • Improved percent-full AAV capsids
  • A straightforward workflow for AAV production platforms

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Mirus Bio